2020 Revenues ($USD) : $49,516,455,427
2020 Revenues (foreign currencies) : CHF 46,491,000,000
2020 R&D spend : $12,164,234,743
2020 Number of Employees : 57,373
Fiscal Year End : 12/31/2020
Key People : Severin Schwan, CEO of Roche Group; William N. (Bill) Anderson, CEO of Roche Pharmaceuticals; Aviv Regev, head of Genentech Research & Early Development (gRED); Dr. William Pao, head of Roche Pharma Research & Early Development (pRED); Dr. James H. Sabry, global head of Pharma Partnering

Roche has long been one of the biggest pharmaceutical companies, but its pharmaceutical sales slumped during the pandemic owing to reduced demand and competition from biosimilars. Growth in its diagnostic division, however, propelled growth for the Basel, Switzerland–based company. In terms of Roche's COVID-19 response, the company quickly positioned its arthritis drug Actemra (tocilizumab) as a potential novel coronavirus treatment. Clinical trial data for that indication, however, have been mixed. The company also worked with partners, including the University of California, San Francisco and Scripps Research, to explore the potential of FDA-approved and pipeline drugs against SARS-CoV-2. The company has also contributed to the National Institutes of Health ACTIV COVID-19 research project. –BB